Exscientia plc (NASDAQ:EXAI) Shares Sold by Values First Advisors Inc.

Values First Advisors Inc. cut its position in Exscientia plc (NASDAQ:EXAI) by 3.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,686 shares of the company’s stock after selling 2,129 shares during the quarter. Values First Advisors Inc.’s holdings in Exscientia were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXAI. GAMMA Investing LLC increased its position in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock worth $25,000 after acquiring an additional 2,302 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new stake in Exscientia during the 2nd quarter worth approximately $54,000. International Assets Investment Management LLC acquired a new position in shares of Exscientia in the 3rd quarter valued at approximately $77,000. Federated Hermes Inc. purchased a new position in shares of Exscientia during the 2nd quarter valued at approximately $115,000. Finally, EntryPoint Capital LLC grew its position in shares of Exscientia by 22.8% during the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after buying an additional 5,784 shares in the last quarter. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on EXAI shares. Barclays reaffirmed an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen restated a “hold” rating on shares of Exscientia in a research note on Friday, August 9th.

Exscientia Price Performance

Shares of NASDAQ EXAI opened at $4.80 on Friday. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $580.26 million, a price-to-earnings ratio of -3.66 and a beta of 0.84. Exscientia plc has a twelve month low of $3.80 and a twelve month high of $7.91. The business has a 50 day simple moving average of $5.12 and a 200-day simple moving average of $5.06.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. The business had revenue of $5.60 million for the quarter. As a group, equities research analysts expect that Exscientia plc will post -1.25 earnings per share for the current year.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.